Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-N-methylpyridine-2-carboxamide (AZD5305): A PARP1–DNA Trapper with High Selectivity for PARP1 over PARP2 and Other PARPs
Jeffrey W. Johannes, Amber Balazs, Derek Barratt, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 19, pp. 14498-14512
Closed Access | Times Cited: 90

Showing 1-25 of 90 citing articles:

DNA repair defects in cancer and therapeutic opportunities
Jessica L. Hopkins, Li Lan, Lee Zou
Genes & Development (2022) Vol. 36, Iss. 5-6, pp. 278-293
Open Access | Times Cited: 121
Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper
Giuditta Illuzzi, Anna D. Staniszewska, Sonja J. Gill, et al.
Clinical Cancer Research (2022) Vol. 28, Iss. 21, pp. 4724-4736
Open Access | Times Cited: 96
ADP-ribosylation from molecular mechanisms to therapeutic implications
Marcin J. Suskiewicz, Evgeniia Prokhorova, J.G.M. Rack, et al.
Cell (2023) Vol. 186, Iss. 21, pp. 4475-4495
Open Access | Times Cited: 75
PARP Inhibitors for Breast Cancer Treatment
Stefania Morganti, Antonio Marra, Carmine De Angelis, et al.
JAMA Oncology (2024) Vol. 10, Iss. 5, pp. 658-658
Closed Access | Times Cited: 22
New Horizons of Synthetic Lethality in Cancer: Current Development and Future Perspectives
Viola Previtali, Greta Bagnolini, Andrea Ciamarone, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 14, pp. 11488-11521
Open Access | Times Cited: 17
Captured snapshots of PARP1 in the active state reveal the mechanics of PARP1 allostery
Élise Rouleau-Turcotte, Dragomir B. Krastev, Stephen J. Pettitt, et al.
Molecular Cell (2022) Vol. 82, Iss. 16, pp. 2939-2951.e5
Open Access | Times Cited: 43
Design and Preclinical Evaluation of a Novel B7-H4–Directed Antibody–Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305
Krista Kinneer, Philipp Wortmann, Zachary A. Cooper, et al.
Clinical Cancer Research (2022) Vol. 29, Iss. 6, pp. 1086-1101
Open Access | Times Cited: 39
Clinical PARP inhibitors allosterically induce PARP2 retention on DNA
Marie-France Langelier, Xiaohui Lin, Shan Zha, et al.
Science Advances (2023) Vol. 9, Iss. 12
Open Access | Times Cited: 32
Mechanism of PARP inhibitor resistance and potential overcoming strategies
Xiaoyu Fu, Ping Li, Qi Zhou, et al.
Genes & Diseases (2023) Vol. 11, Iss. 1, pp. 306-320
Open Access | Times Cited: 29
An Analysis of Successful Hit-to-Clinical Candidate Pairs
Dean G. Brown
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 11, pp. 7101-7139
Closed Access | Times Cited: 26
ADP-ribose contributions to genome stability and PARP enzyme trapping on sites of DNA damage; paradigm shifts for a coming-of-age modification
Élise Rouleau-Turcotte, John M. Pascal
Journal of Biological Chemistry (2023) Vol. 299, Iss. 12, pp. 105397-105397
Open Access | Times Cited: 25
New Life of Topoisomerase I Inhibitors as Antibody–Drug Conjugate Warheads
Yves Pommier, Anish Thomas
Clinical Cancer Research (2023) Vol. 29, Iss. 6, pp. 991-993
Open Access | Times Cited: 23
The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer models
Andrea Herencia-Ropero, Alba Llop‐Guevara, Anna D. Staniszewska, et al.
Genome Medicine (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 15
BRCAness, DNA gaps, and gain and loss of PARP inhibitor–induced synthetic lethality
Xin Li, Lee Zou
Journal of Clinical Investigation (2024) Vol. 134, Iss. 14
Open Access | Times Cited: 13
Poly (ADP-ribose) polymerase (PARP) inhibitors as anticancer agents: An outlook on clinical progress, synthetic strategies, biological activity, and structure-activity relationship
Pronoy Kanti Das, Gurubasavaraja Swamy Purawarga Matada, Rohit Pal, et al.
European Journal of Medicinal Chemistry (2024) Vol. 274, pp. 116535-116535
Closed Access | Times Cited: 12
Thioparib inhibits homologous recombination repair, activates the type I IFN response, and overcomes olaparib resistance
Limin Wang, Pingyuan Wang, X. T. Chen, et al.
EMBO Molecular Medicine (2023) Vol. 15, Iss. 3
Open Access | Times Cited: 21
A universal programmable Gaussian boson sampler for drug discovery
Shang Yu, Zhipeng Zhong, Yuhua Fang, et al.
Nature Computational Science (2023) Vol. 3, Iss. 10, pp. 839-848
Open Access | Times Cited: 21
Design of Selective PARP-1 Inhibitors and Antitumor Studies
Yiting Zhang, Xiangqian Li, Fang Liu, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 11, pp. 8877-8901
Closed Access | Times Cited: 7
Comprehensive machine learning boosts structure-based virtual screening for PARP1 inhibitors
Klaudia Caba, Viet‐Khoa Tran‐Nguyen, Taufiq Rahman, et al.
Journal of Cheminformatics (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 6
Medicinal Chemistry Perspective on Targeting Mono-ADP-Ribosylating PARPs with Small Molecules
Maria Giulia Nizi, Mirko M. Maksimainen, L. Lehtiö, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 11, pp. 7532-7560
Open Access | Times Cited: 25
Selective PARP1 inhibitors, PARP1-based dual-target inhibitors, PROTAC PARP1 degraders, and prodrugs of PARP1 inhibitors for cancer therapy
Xiaopeng Peng, Wanyi Pan, Feng Jiang, et al.
Pharmacological Research (2022) Vol. 186, pp. 106529-106529
Closed Access | Times Cited: 24
Olaparib and advanced ovarian cancer: Summary of the past and looking into the future
Brigida Anna Maiorano, Mauro Francesco Pio Maiorano, Evaristo Maiello
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 16
PARP-1: a critical regulator in radioprotection and radiotherapy-mechanisms, challenges, and therapeutic opportunities
Wenhao Li, Fei Wang, Gui-yuan Song, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 15
Preclinical Characterization of AZD9574, a Blood–Brain Barrier Penetrant Inhibitor of PARP1
Anna D. Staniszewska, Domenic Pilger, Sonja J. Gill, et al.
Clinical Cancer Research (2023) Vol. 30, Iss. 7, pp. 1338-1351
Closed Access | Times Cited: 15
Targeting homologous recombination deficiency in uterine leiomyosarcoma
Genevieve Dall, Cassandra J. Vandenberg, Ksenija Nesic, et al.
Journal of Experimental & Clinical Cancer Research (2023) Vol. 42, Iss. 1
Open Access | Times Cited: 14
Page 1 - Next Page

Scroll to top